PR-DUB belongs to the Josephin family of deubiquitinases, which are characterized by a conserved catalytic domain. The catalytic mechanism of PR-DUB involves the use of a cysteine protease to cleave the isopeptide bond between the ubiquitin and the lysine residue on the histone. PR-DUB specifically recognizes the H2AK119 ubiquitination mark and removes it without affecting other ubiquitination sites on the nucleosome.
The activity of PR-DUB is regulated by various mechanisms, including post-translational modifications and protein interactions. For example, phosphorylation of PR-DUB by protein kinase A (PKA) has been shown to increase its activity, while binding to the protein polycomb repressive complex 2 (PRC2) can inhibit its activity.
PR-DUB plays a critical role in gene regulation by removing the H2AK119 ubiquitination mark, which is associated with gene repression. By removing this mark, PR-DUB allows for the transcription of genes that are normally silenced by the presence of H2AK119 ubiquitination.
Dysregulation of PR-DUB activity has been linked to various diseases, including cancer and developmental disorders. Therefore, PR-DUB is considered a potential therapeutic target for the treatment of these diseases. Small molecule inhibitors of PR-DUB are being developed as potential drugs to modulate gene expression and restore normal cellular function.
Overall, PR-DUB is a key enzyme in the regulation of gene expression through its specific removal of H2AK119 ubiquitination on the nucleosome. Further research on PR-DUB and its regulation may provide new insights into the mechanisms of gene regulation and lead to the development of novel therapeutic strategies for various diseases.
